We are a clinical-stage company that is focused on developing new therapeutics to fight cancer using the immune system. Our product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. Our main disease focus using our immunotherapy technologies is to treat glioblastoma, but these therapies may also be applicable to multiple other cancers such as pancreatic, colon and breast cancers due to presence of similar epitopes on these malignant cells. Our antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer.

Our primary focus is on the development of a therapeutic vaccine targeting cancer stem cells for multiple cancer indications, and we expect to file an Investigational New Drug (IND) application in the third quarter of 2009 to begin a Phase 1 clinical trial. We have an exclusive worldwide license from Cedars-Sinai Medical Center for our immunotherapy technologies as well as cancer stem cell technologies.